SecSonar.com

NeurAxis, Inc. (NRXS)

NeurAxis, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

NeurAxis, Inc. (NRXS) is a Biotechnology company based in US with a market capitalization of $89.9M. Revenue grew 32.9% year-over-year and free cash flow was negative at -$6.5M. This page tracks NRXS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 21 employees · IPO Aug 9, 2023

Valuation

Valuation & price

$7.87 · as of May 17, 2026 · -10.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

26.45

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$8.81$5.57$2.33Jul 25Dec 25Jul 26Jul 7, 25$2.70Jul 9, 25$2.42Jul 11, 25$2.40Jul 15, 25$2.46Jul 17, 25$2.72Jul 21, 25$2.73Jul 23, 25$2.76Jul 25, 25$2.77Jul 29, 25$2.62Jul 31, 25$2.62Aug 4, 25$2.52Aug 6, 25$2.49Aug 11, 25$2.43Aug 13, 25$2.46Aug 15, 25$2.41Aug 19, 25$2.36Aug 21, 25$2.33Aug 25, 25$2.54Aug 27, 25$2.42Aug 29, 25$2.54Sep 3, 25$2.54Sep 5, 25$2.43Sep 9, 25$2.45Sep 11, 25$2.42Sep 16, 25$2.43Sep 18, 25$2.61Sep 22, 25$2.69Sep 24, 25$2.69Sep 26, 25$2.99Sep 30, 25$3.08Oct 2, 25$3.19Oct 6, 25$3.15Oct 8, 25$3.13Oct 10, 25$2.98Oct 14, 25$3.03Oct 16, 25$3.14Oct 21, 25$3.70Oct 23, 25$3.82Oct 27, 25$3.11Oct 29, 25$3.02Oct 31, 25$2.72Nov 4, 25$2.54Nov 6, 25$2.53Nov 10, 25$2.56Nov 12, 25$2.60Nov 14, 25$2.34Nov 18, 25$2.40Nov 20, 25$2.51Nov 25, 25$2.65Nov 28, 25$2.78Dec 2, 25$2.68Dec 4, 25$2.71Dec 8, 25$2.63Dec 10, 25$2.76Dec 12, 25$2.65Dec 16, 25$2.70Dec 18, 25$2.88Dec 22, 25$4.03Dec 24, 25$3.82Dec 29, 25$4.20Jan 2, 26$4.46Jan 6, 26$4.46Jan 8, 26$4.63Jan 12, 26$5.15Jan 14, 26$4.74Jan 16, 26$4.57Jan 21, 26$4.91Jan 23, 26$4.86Jan 27, 26$4.57Jan 29, 26$4.65Feb 2, 26$4.42Feb 4, 26$4.35Feb 9, 26$4.36Feb 11, 26$4.65Feb 13, 26$4.91Feb 18, 26$5.36Feb 20, 26$5.53Feb 24, 26$5.01Feb 26, 26$5.69Mar 2, 26$6.30Mar 4, 26$5.81Mar 6, 26$5.71Mar 10, 26$6.31Mar 12, 26$6.48Mar 17, 26$7.21Mar 19, 26$7.16Mar 23, 26$7.31Mar 25, 26$7.51Mar 27, 26$6.90Mar 31, 26$7.40Apr 2, 26$7.25Apr 7, 26$7.34Apr 9, 26$7.25Apr 13, 26$6.99Apr 15, 26$7.00Apr 17, 26$7.22Apr 22, 26$7.51Apr 24, 26$7.86Apr 28, 26$7.61Apr 30, 26$7.45May 4, 26$8.30May 6, 26$8.81May 8, 26$8.20May 12, 26$8.27May 14, 26$8.35May 18, 26$7.41May 20, 26$7.25May 22, 26$7.38May 28, 26$7.29Jun 1, 26$7.34Jun 3, 26$7.07Jun 5, 26$6.84Jun 9, 26$6.80Jun 11, 26$6.89Jun 15, 26$6.80Jun 17, 26$6.71Jun 22, 26$7.16Jun 24, 26$6.80Jun 26, 26$7.27Jul 2, 26$7.06
$2.3152-week range$8.81
Loading valuation history…

Fundamentals

Key fundamentals

$89.9M

Market cap

32.9%

Revenue growth (YoY)

84.2%

Gross margin

-$6.5M

Free cash flow (USD)

-$4.5M

Net debt

Net cash position

31.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2020 → 2025

FY 2020$1.9MFY 2021$2.7MFY 2022$2.7MFY 2023$2.5MFY 2024$2.7MFY 2025$3.6M
$1.9M$3.6M

Free cash flow by year

2020 → 2025

FY 2020$-4.2MFY 2021$-2.2MFY 2022$-2.4MFY 2023$-6.8MFY 2024$-6.1MFY 2025$-6.5M
-$4.2M-$6.5M

Gross margin by year

2021 → 2025

FY 202182.8%FY 202288.9%FY 202387.7%FY 202486.5%FY 202584.2%
82.8%84.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventIncentive Plan AmendmentJun 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • 8-K eventAt The Market Offering UpdateApr 22, 2026Filing
  • 8-K eventEarnings ReleaseApr 21, 2026Filing
  • Insider buyInsider Buy $16KCarrico Brian Allen · Director, Chief Executive Officer · $15.8KApr 3, 2026Filing
  • Insider buyInsider Buy $1KCarrico Thomas Joeseph · CRO, CCO, CPO · $1.3KApr 3, 2026Filing
  • Insider buyInsider Buy $15KHenrichs Timothy Robert · Chief Financial Officer · $14.9KApr 3, 2026Filing

Questions

Frequently asked questions

What is NeurAxis, Inc.'s market cap?

NeurAxis, Inc. (NRXS) has a market capitalization of $89.9M.

What is NRXS's P/E ratio?

A meaningful P/E ratio is not available for NRXS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NRXS's price-to-book (P/B) ratio?

NRXS trades at 26.45 times book value per share.

Are insiders buying NRXS stock?

SEC Form 4 filings show no open-market insider buys at NeurAxis, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

ICCC

ImmuCell Corporation

$89.6M

DTIL

Precision BioSciences, Inc.

$89.5M

ANIX

Anixa Biosciences, Inc.

$92.2M

VTVT

vTv Therapeutics Inc.

$86.7M

FBIO

Fortress Biotech, Inc.

$93.3M

COYA

Coya Therapeutics, Inc.

$86.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.